On Jan. 3, the Indian government granted emergency use authorization for the COVID-19 vaccine Covaxin developed by Bharat Biotech International Ltd. Indian news media praised the move, calling it the pride of the nation.
Covaxin was researched and developed by Bharat Biotech in collaboration with India’s National Institute of Virology and the Indian Council of Medical Research, using the same technology platform as China’s vaccines.
The institute and the council provided the virus strain in May last year, and in July commenced phase 1 and phase 2 clinical trials, which were carried out in 12 Indian hospitals selected by the council.
The results of the phase 1 clinical trials, which were published in the British journal The Lancet Infectious Diseases, showed that there was a good immune response to the vaccine in non-human primates. The phase 3 clinical trial began in November, and data were collected on 25,800 people in 22 Indian hospitals. It is expected to be completed next month.
However, the Drugs Controller General of India and the Central Drugs Standard Control Organization on Jan. 3 accepted the recommendations of an expert committee and granted advance approval for emergency use.
Many Indian experts and academic organizations, headed by the nation’s most famous virologist, Gagandeep Kang, objected to the decision.
Lawmaker Shashi Tharoor, a senior member of the opposition Indian National Congress party, also voiced his disagreement.
Paul Griffin, director of infectious diseases at the University of Queensland in Australia, said that he had never heard of any precedent of approving emergency use of a vaccine before completion of its phase 3 clinical trial.
As of Feb. 4, the Indian Ministry of Health and Family Welfare had been notified of 25 hospitalizations and 19 deaths of people who had received the vaccine, but Minister of Health and Family Welfare Harsh Vardhan said that the deaths were not causally related to COVID-19 vaccination and that any adverse reactions to the vaccine were minor.
Taiwan’s most experienced pharmaceutical company, Adimmune Biotech Corp, held its phase 1 clinical trial, led by professor Chang Shan-chwen (張上淳) at National Taiwan University Hospital, but discontinued the project after finding that the vaccine did not produce a satisfactory immune response. Adimmune and its research team are to be commended for their honest attitude.
On Jan. 26, US pharmaceutical firm Merck announced, for the same reason, that it had discontinued a vaccine research project it had been conducting in cooperation with France’s Pasteur Institute.
It should be noted that Merck is a well-known company with a long history and experience of making and selling vaccines, while the Pasteur Institute was the first institute in the world to engage in vaccine research.
The Food and Drug Administration has recommended that the government should purchase 10 million doses of the Taiwan-made vaccine that will definitely not proceed to its phase 3 clinical trial.
Minister of Health and Welfare Chen Shih-chung (陳時中) should give serious thought to his administrative and legal responsibilities. He should consider conducting a public opinion poll on people’s willingness to accept a Taiwan-made vaccine.
An even better idea would be to use the real-name mask rationing system for the public to register their willingness to accept locally made vaccines, to find out how many people would be willing to do so, and only then decide how many doses of which vaccine to order.
Hsieh Yen-yau is a retired professor of internal medicine at National Taiwan University College of Medicine.
Translated by Julian Clegg
George Santayana wrote: “Those who cannot remember the past are condemned to repeat it.” This article will help readers avoid repeating mistakes by examining four examples from the civil war between the Chinese Communist Party (CCP) forces and the Republic of China (ROC) forces that involved two city sieges and two island invasions. The city sieges compared are Changchun (May to October 1948) and Beiping (November 1948 to January 1949, renamed Beijing after its capture), and attempts to invade Kinmen (October 1949) and Hainan (April 1950). Comparing and contrasting these examples, we can learn how Taiwan may prevent a war with
Taiwan is rapidly accelerating toward becoming a “super-aged society” — moving at one of the fastest rates globally — with the proportion of elderly people in the population sharply rising. While the demographic shift of “fewer births than deaths” is no longer an anomaly, the nation’s legal framework and social customs appear stuck in the last century. Without adjustments, incidents like last month’s viral kicking incident on the Taipei MRT involving a 73-year-old woman would continue to proliferate, sowing seeds of generational distrust and conflict. The Senior Citizens Welfare Act (老人福利法), originally enacted in 1980 and revised multiple times, positions older
The Chinese Nationalist Party (KMT) has its chairperson election tomorrow. Although the party has long positioned itself as “China friendly,” the election is overshadowed by “an overwhelming wave of Chinese intervention.” The six candidates vying for the chair are former Taipei mayor Hau Lung-bin (郝龍斌), former lawmaker Cheng Li-wen (鄭麗文), Legislator Luo Chih-chiang (羅智強), Sun Yat-sen School president Chang Ya-chung (張亞中), former National Assembly representative Tsai Chih-hong (蔡志弘) and former Changhua County comissioner Zhuo Bo-yuan (卓伯源). While Cheng and Hau are front-runners in different surveys, Hau has complained of an online defamation campaign against him coming from accounts with foreign IP addresses,
Taiwan’s business-friendly environment and science parks designed to foster technology industries are the key elements of the nation’s winning chip formula, inspiring the US and other countries to try to replicate it. Representatives from US business groups — such as the Greater Phoenix Economic Council, and the Arizona-Taiwan Trade and Investment Office — in July visited the Hsinchu Science Park (新竹科學園區), home to Taiwan Semiconductor Manufacturing Co’s (TSMC) headquarters and its first fab. They showed great interest in creating similar science parks, with aims to build an extensive semiconductor chain suitable for the US, with chip designing, packaging and manufacturing. The
RSS